About this Journal Submit a Manuscript Table of Contents

Low-risk Thyroid Cancer Treatment

Call for Papers

Differentiated thyroid cancer (DTC) is a generally indolent disease, although cases with certain clinicopathological features are progressive and life-threatening. Currently, the treatment strategies of DTC are quite uniform worldwide: total thyroidectomy, radioactive iodine (RAI) ablation, and thyroid-stimulating hormone (TSH) suppression. Such a stereotyped treatment might be easy for physicians, but it might be an overtreatment for many DTC patients without high-risk features and predicting an excellent prognosis. Recently, in some institutions, trials of observation and limited surgery for low-risk patients have been performed, and the dose of RAI for ablation came to be reduced for patients who were classified as low-risk based on clinicopathologic features. Unfortunately, comparable studies are very hard to perform, but therapeutic experience for low-risk DTC patients is now being accumulated in many institutions.

We invite papers demonstrating an experience of treatment for low-risk DTC patients in the fields of surgery, radiology, pathology, and endocrinology. Potential topics include, but are not limited to:

  • Limited surgery for low-risk DTC: extent of thyroidectomy and prophylactic lymph node dissection
  • Indication of completion total thyroidectomy for patients who underwent limited surgery under the diagnosis of adenomatous nodule or follicular tumor but were pathological diagnosed as follicular (or papillary) carcinoma
  • Indication of postoperative RAI ablation for low-risk DTC patients: its necessity or unnecessity and dose of RAI
  • Indication of TSH suppression therapy: its necessity or unnecessity and appropriate TSH levels
  • Relationship between pathological examination and prognosis of low-risk DTC patients
  • How to follow low-risk DTC patients after surgery (and RAI ablation): constant examination by specialist is necessary?

Before submission authors should carefully read over the journal's Author Guidelines, which are located at http://www.hindawi.com/journals/jtr/guidelines/. Prospective authors should submit an electronic copy of their complete manuscript through the journal Manuscript Tracking System at http://mts.hindawi.com/submit/journals/jtr/lrtc/ according to the following timetable:

Manuscript DueFriday, 25 January 2013
First Round of ReviewsFriday, 19 April 2013
Publication DateFriday, 14 June 2013

Lead Guest Editor

  • Yasuhiro Ito, Department of Surgery, Kuma Hospital, Kobe, Japan

Guest Editors

  • R. Michael Tuttle, Memorial Sloan-Kettering Cancer Center, Cornell University Medical College, New York, NY, USA
  • Hang-Seok Chang, Gangnam Severance Hospital, Yonsei University, Seoul, Republic of Korea